Pathology & Oncology Research

, Volume 6, Issue 4, pp 301–312 | Cite as

Coagulation and cancer: Implications for diagnosis and management

  • M. F. Loreto
  • Massimo De Martinis
  • M. P. Corsi
  • M. Modesti
  • L. Ginaldi


Coagulation disorders are a common problem in neoplastic patients and many factors contribute to increase the risk of thromboembolic events in these patients. An hypercoagulable state is induced by malignant cells interacting directly with hemostatic system and activating the coagulation cascade. More sensitive tests to assess an hypercoagulable state in cancer patients have been developed; even though these tests are always altered in cancer patients, none of them possess a clinical significance in terms of predictive value for the occurence of thromboembolism and disease prognosis in the individual patient. The most frequent thromboembolic complications in cancer patients are deep vein thrombosis of the lower extremities and pulmonary embolism; therefore, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura or haemolytic uremic syndrome are special manifestations of neoplastic disease. Diagnosis of idiopathic deep vein thrombosis, in the absence of other risk factors, could indicate the presence of occult malignant disease; however, the need for an extensive work-up to detect malignancy is still controversial. Neoplastic patients showing a thromboembolic event should be treated with unfractioned heparin or, alternatively, with low molecular weight heparins. In order to prevent recurrence, the administration of heparin should be associated and followed by an oral anticoagulant drug. In recent years new approaches in anti-aggregation therapy have been studied, such as COX-inhibitors, cicaprost and ReoPro; further studies are needed to determine the usefulness of these molecules in treatment of malignancies.


thrombosis malignancy haemostasis oncology therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.2
    Adany R: Intracellular factor XIII: cellular distribution of factor XIII subunit A in humans. Semin Thromb Hemost 22:399–408, 1996.PubMedCrossRefGoogle Scholar
  2. 2.2
    Bardos H, Juhansz A, Repassy G, et al: Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx. Thromb Haemost 80:767–772, 1998.PubMedGoogle Scholar
  3. 3.2
    Baron JA, Gridley G, Weiderpas E, et al: Venous thromboembolism and cancer. Lancet 351:1077–1080, 1998.PubMedCrossRefGoogle Scholar
  4. 4.2
    Bastida E, Ordinas A, Jamieson GA: Differing platelets aggregating effects by two tumor cells lines: absence of a role for platelet-derived ADP. Am J Hematol 11:367–378, 1981.PubMedCrossRefGoogle Scholar
  5. 5.2
    Bergqvist D, Burmark US: Low-molecular-weight heparin started before surgery as prophylaxis against deep-vein thrombosis: 2500 versus 5000 anti-Xa units in 2070 patients. Br J Surg 82:496–501, 1995.PubMedCrossRefGoogle Scholar
  6. 6.2
    Bertomeu MC, Gallo S, Lauri D Levine MN, et al: Chemotherapy enhances endothelial reactivity to platelets. Clin Expl Metastasis 8:511–518, 1990.CrossRefGoogle Scholar
  7. 7.2
    Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost 5:1–26, 1978.PubMedGoogle Scholar
  8. 8.2
    Bottasso B, Mari D, Coppola R, et al: Hypercoagulability and hyperfibrinolysis in patients with melanoma. Thromb Res 81:345–352, 1996.PubMedCrossRefGoogle Scholar
  9. 9.2
    Brown LE, Detmar M, Claffey KP: Vascular permeability factor/vascular endothelial growht factor: a multifunctional angiogenesis factor. In: Goldberg ID, Rosen EM, eds. Regulation of Angiogenesis. Basel Birgkhauser Verlag, 233–269;Google Scholar
  10. 10.2
    Buccheri G, Ferrigno D, Ginardi C, et al: Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer 33:50–55, 1997.PubMedCrossRefGoogle Scholar
  11. 11.2
    Calvo FA, Hidalgo OF, Gonzales F, et al: Urokinase combination chemotherapy in small cell lung cancer. A phase II study. Cancer 70:2624–2630, 1992.PubMedCrossRefGoogle Scholar
  12. 12.2
    Carey MG, Rodgers GM: Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol 59:65–73, 1998.PubMedCrossRefGoogle Scholar
  13. 13.2
    Chahinian AP, Propert KJ, Ware JH, et al: A randomized trial of anticoagulation with warfarin and alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7:993–1002, 1989.PubMedGoogle Scholar
  14. 14.2
    Chan A, Woodruff RK: Complication and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Aust NZ J Med 22:119–122, 1992.Google Scholar
  15. 15.2
    Chen YQ, Trikha M, Gao X, et al: Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin. Int J Cancer 72:642–648, 1997PubMedCrossRefGoogle Scholar
  16. 16.2
    Clauss M, Gerlach M, Geralach H, et al: Vascular permeabiliy factor: a tumor-derived polypeptide that induce endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535–1545, 1990.PubMedCrossRefGoogle Scholar
  17. 17.2
    Colman RW, Rubin RN: Disseminated intravascular coagulation due to malignancy. Semin Oncol 17:140–146, 1990.Google Scholar
  18. 18.2
    Cornuz J, Pearson SD, Creager MA, et al: Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 60:257–277, 1996.Google Scholar
  19. 19.2
    Cybulsky MI, Chan MKW, Movat HZ. Acute inflammation and microthrombosis induced by endotoxin, interleukin-1 and tumor necrosis factor and their implication in gram negative infection. Lab Invest 58:365–368, 1988.PubMedGoogle Scholar
  20. 20.2
    DeLisser HM, Christofidou-Solomidou M, Strieter RM, et al: Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am JPathol 151:671–677, 1997Google Scholar
  21. 21.2
    Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 75:329–336, 1990.PubMedGoogle Scholar
  22. 22.2
    Dolovich L, Ginsberg JS: Low-molecular weight heparins in the treatment of venous thromboembolism. Vessels 3:4–11, 1997.Google Scholar
  23. 23.2
    Donati MB, Gambacorti-Passerinin C, et al: Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Res 46: 6471–6474, 1986.PubMedGoogle Scholar
  24. 24.2
    Edwards RL, Rickles FR, Cronlund M: Mononuclear cell tissue factor generation. J Lab Clin Med 98:917–928, 1981.PubMedGoogle Scholar
  25. 25.2
    Eldor A: Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. Baillieres Clin Haematol 11:475–495, 1998.PubMedCrossRefGoogle Scholar
  26. 26.2
    ENOXAN Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep-vein thrombosis in elective cancer surgery: a double-blind randomised multicentre trial with venography assessment. Br J Surg 84:1099–1103, 1997.CrossRefGoogle Scholar
  27. 27.2
    Esmon CT: Possible involvment of cytokines indiffuse intravascular coagulation and thrombosis. Baillieres Clin Haematol 7:453–468, 1994.PubMedCrossRefGoogle Scholar
  28. 28.2
    Falanga A, Rickles FR: Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25:173–182, 1999.PubMedCrossRefGoogle Scholar
  29. 29.2
    Fisher B, Costantino JP, Wickerham L, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Projects P-1 Study. J Natl Cancer Inst 90:1371–1388, 1998.PubMedCrossRefGoogle Scholar
  30. 30.2
    Fournier DB, Gordon GB: COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem Suppl 34:97–102, 2000.PubMedCrossRefGoogle Scholar
  31. 31.2
    Francis JL, Biggerstaff J, Amirkhosravi A: Hemostasis and Malignancy. Semin Thromb Hemost 24:93–109, 1998.PubMedCrossRefGoogle Scholar
  32. 32.2
    Frishman WH, Burns B, Atac B, et al: Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa receptor. Am Heart J 130:877–892, 1995.PubMedCrossRefGoogle Scholar
  33. 33.2
    Ghosh BC, Chiffon EE: Malignant tumors with superior vena cava obstruction. NY State J Med 73:283–289, 1973.Google Scholar
  34. 34.2
    Girolami A, Prandoni P, Zanon E, et al: Venous thrombosis of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs. Blood Coagul Fibrinolysis 10:455–457, 1999.PubMedCrossRefGoogle Scholar
  35. 35.2
    Glassman AB: Hemostatic abnormalities associated with cancer and its therapy. Ann Clin Lab Sci 27:391–395, 1997.PubMedGoogle Scholar
  36. 36.2
    Goldeberg MA, Ginsburg D, Mayer RJ, et al: Is Heparin administration necessary during induction chemotherapy for patients with acute promielocytic leukaemia? Blood 69:187–191, 1987.Google Scholar
  37. 37.2
    Goldeberg RJ, Seneff M, Gore JM, et al: Occult malignant neoplasm in patients with deep vein thrombosis. Arch Intern Med 147:251–253, 1987.CrossRefGoogle Scholar
  38. 38.2
    Gordon LI, Kwaan HC: Thrombotic microangiopaty manifesting as thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost 25:217–221, 1999.PubMedCrossRefGoogle Scholar
  39. 39.2
    Gouin-Thibault I, Samama MM: Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Haemost 25:167–172, 1999.CrossRefGoogle Scholar
  40. 40.2
    Gralnick HR, Abrell BA: Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br J Hematol 24:89–99, 1973.CrossRefGoogle Scholar
  41. 41.2
    Griffin MR, Stanson AW, Brown ML, et al: FJ. Deep-vein thrombosis and pulmonary embolism: risk of subsequent malignant neoplasms. Arch Intern Med 147:1907–1901, 1987.PubMedCrossRefGoogle Scholar
  42. 42.2
    Hayes R, Chesebro JH, Fuster V, et al: Anthithrombotic effects of abciximab. Am J Cardiol 85:1167–1172, May 2000.PubMedCrossRefGoogle Scholar
  43. 43.2
    Hasui Y, Marutsuka K, Nishi S, et al: The content of urokinasetype plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 151:16–19; 1994.PubMedGoogle Scholar
  44. 44.2
    Hejna M, Raderer M, Zielinski CC: Inhibition of metastases by anticoagulants. JNCI 91:22–36, 1999.PubMedGoogle Scholar
  45. 45.2
    Hienert G, Kirchheimer JC, Christ G, et al: Plasma urokinasetype plasminogen activator correlates to bone scintigraphy in prostatic carcinoma. Eur Urol 15:256–258, 1988.PubMedGoogle Scholar
  46. 46.2
    Hiettarachchi JK, Lok J, Prins MH, et al: Undiagnosed malignancy in patients with deep vein thrombosis, Cancer 83:180–185, 1998.CrossRefGoogle Scholar
  47. 47.2
    Honn KV, Busse WD, Sloane BE Prostacyclin and thromboxane. Implications for their role in tumor cell metastasis. Biochem Pharmacol 32:1–11, 1983.PubMedCrossRefGoogle Scholar
  48. 48.2
    Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science 212:1270–1272, 1981.PubMedCrossRefGoogle Scholar
  49. 49.2
    Honn KV, Tang DG, Crissman JD: Platelets and cancer metastasis: a casual relationship? Cancer Metastasis Rev 11:325–351, 1992.PubMedCrossRefGoogle Scholar
  50. 50.2
    Hotton KM, Khorsand M, Hank JA, et al: A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary métastases: a case of fatal central nervous system thrombosis. Cancer 88:1892–1901, 2000.PubMedCrossRefGoogle Scholar
  51. 51.2
    Hull R, Delmore T, Carter C, et al: Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis. N Engl J Med 306:189–194, 1982.PubMedGoogle Scholar
  52. 52.2
    Kakkar AK, Williamson RCN: Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 25:239–244, 1999.PubMedCrossRefGoogle Scholar
  53. 53.2
    Karpakin S, Perlstein E: Role of platelets in tumor cells métastases. Ann Intern Med 95:636–641, 1981.Google Scholar
  54. 54.2
    Lacotte L, Thierry A, Delwail V, et al: Thrombotic thrombocytopenic purpura during interferon alpha tretment for chronic myelogenous leukemia. Acta Haematol 102:160–162; 2000.PubMedCrossRefGoogle Scholar
  55. 55.2
    Lebeau B, Chastang CL, Brechot JM: Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer. Lung Cancer 7 (Suppl): 129–134, 1991.Google Scholar
  56. 56.2
    Lee AYY, Levine MN: The thrombophilic state induced by therapeutic agents. Semin Thromb Haemost 25:137–145, 1999.CrossRefGoogle Scholar
  57. 57.2
    Levine M, Gent M, Hirsh J, et al: A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 334:677–681, 1996.PubMedCrossRefGoogle Scholar
  58. 58.2
    Levine M, Hirsh J, Gent M, et al: Double-bind randomized trial of very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886–889, 1994.PubMedCrossRefGoogle Scholar
  59. 59.2
    Levine M, Hirsh J: The diagnosis and treatment of thrombosis in the cancer patient. Semin Oncol 17:160–171, 1990.PubMedGoogle Scholar
  60. 60.2
    Levine MN, Lee AYY: Treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost 25:245–249, 1999.PubMedCrossRefGoogle Scholar
  61. 61.2
    Lhindal AK, Sandset PM, Abildgaard U: Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction. Haemostasis 20:253–262, 1990.Google Scholar
  62. 62.2
    Lopez Y, Paloma MJ, Rifon J, et al: Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 15:71–78, 1999.CrossRefGoogle Scholar
  63. 63.2
    Ludwig J, Kentos A, Creiner L, et al: Disseminated intravascular coagulation syndrome as manifestation of breast adenocarcinoma metastasis. Rev Med Brux 18:385–388, 1997.PubMedGoogle Scholar
  64. 64.2
    Luzzatto G, Schafer AI: The prethrombotic state in cancer. Seminars in Ocology 17:147–159, 1990.Google Scholar
  65. 65.2
    Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60(5): 1306–11; 2000.PubMedGoogle Scholar
  66. 66.2
    Min KW, Gyorkey F Sato C: Mucin producing adenocarcinomas and nonbacterial thrombotic endocarditis. Cancer 45:2374–2382; 1980.PubMedCrossRefGoogle Scholar
  67. 67.2
    Miyake H, Hara I, Yamanaka K, et al. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 14:535–541, 1999.PubMedGoogle Scholar
  68. 68.2
    Monreal M, Lafoz E, Casals A, et al: Occult cancer in patients with deep vein thrombosis: a systematic approach. Cancer 67:541–545, 1991.PubMedCrossRefGoogle Scholar
  69. 69.2
    Monreal M, Prandoni P: Venous thromboembolism as first manifestation of cancer. Semin Thromb Hemost 25:131–136; 1999.PubMedCrossRefGoogle Scholar
  70. 70.2
    Muszbek L, Ádány R, Mikkola H: Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 33:357–421, 1996.PubMedCrossRefGoogle Scholar
  71. 71.2
    Nicholson GL, Custead SE: Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interaction as a model for assessing vascular integrity. Cancer Res 45:331–336, 1985.Google Scholar
  72. 72.2
    Nie D, Tang K, Szekeres K, et al: Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. Ann N Y Acad Sci 905:165–176, 2000.PubMedGoogle Scholar
  73. 73.2
    Newman PJ: The role of PECAM-1 in vascular cell biology. Ann N Y Acad Sci 714:165–174, 1994.PubMedCrossRefGoogle Scholar
  74. 74.2
    Nordstrom M, Lindblad B, Anderson H et al: Deep vein thrombosis and occult malignancy: an epidemiological study. BMJ 308:891–894, 1994.PubMedGoogle Scholar
  75. 75.2
    Oberhoff C, Winkler UH, Tauchert AM, et al: Adjuvant CMF chemotherapy in patients with breast cancer: result on blood coagulation and fibrinolysis. Zentralbl Gynakol 119:211–217, 1997.PubMedGoogle Scholar
  76. 76.2
    O’Connor NT Cederholm-Williams SA, Fletcher EW, et al: Significance of idiopathic deep venous thrombosis. Postgrad Med J 147:1907–1911, 1987.Google Scholar
  77. 77.2
    Ohtake N, Kurita S, Fukabory Y, et al: Clinical study on prostate cancer initially presenting with disseminated intravascular coagulation syndrome. Hinyokika Kiyo 44:387–390, 1998.PubMedGoogle Scholar
  78. 78.2
    Owen CA, Bowie EJW: Chronic intravascular coagulation syndromes, a summary. Mayo Clin Proc 49: 673–679, 1974.PubMedGoogle Scholar
  79. 79.2
    Ozguroglu M, Arun B, Erzin Y, et al: Serum cardiolipin antibodies in cancer patient with thromboembolic events. Clin Appl Thromb Hemost 5:181–184, 1999.PubMedCrossRefGoogle Scholar
  80. 80.2
    Porta C, Danova M, Riccardi A, et al: Cancer Chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 74:570–574, 1999.PubMedCrossRefGoogle Scholar
  81. 81.2
    Prandoni P, Lensing AWA, Buller HR, et al: Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 339:441–445, 1992.PubMedCrossRefGoogle Scholar
  82. 82.2
    Prandoni P, Lensing AWA, Buller HR, et al: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128–1133, 1992.PubMedGoogle Scholar
  83. 83.2
    Prandoni P, Lensing AWA, Cogo Cuppini S, et al: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7; 1996.PubMedGoogle Scholar
  84. 84.2
    Prandoni P, Piccioli A, Girolami A: Cancer and venous thromboembolism: an overview. Hematologica 84:437–445, 1999.Google Scholar
  85. 85.2
    Prandoni P: Antithrombotic strategies in patients with cancer. Thromb Haemost 78:141–144, 1997.PubMedGoogle Scholar
  86. 86.2
    Probst-Cousin S, Rickert CH, Gullotta F: Factor XIIa-immunoreactivity in tumors of the central nervous system. Clin Neuropathol 17:79–84, 1998.PubMedGoogle Scholar
  87. 87.2
    Raveh E, Cohen M, Shpitzer T, et al: Carcinoma of the thyroid: a cause of hypercoagulability? Ear Nose Throat J 74:110–112, 1995.PubMedGoogle Scholar
  88. 88.2
    Rayson D, Ingle JN, Pruthi RH: Thrombosis of the internal jugular vein: a rare manifestation of the hypercoagulability of malignancy. Cancer Invest 16:319–321, 1998.PubMedCrossRefGoogle Scholar
  89. 89.2
    Rella C, Caviello M, Giotta F et al: A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 40:151–159, 1996.PubMedCrossRefGoogle Scholar
  90. 90.2
    Rickles FR, Edwards RL, Barb C, et al: Abnormalities of blood coagulation in patients with cancer. Cancer 51:301–307, 1983.PubMedCrossRefGoogle Scholar
  91. 91.2
    Rickles FR, Levine M, Edwards RL: Hemostatic alterations in cancer patients. Cancer Metastasis Rev 11:237–248, 1992.PubMedCrossRefGoogle Scholar
  92. 92.2
    Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders: Blood 69:187–191, 1987.Google Scholar
  93. 93.2
    Schneider MR, Schirner M: Antimetastatic prostacyclin analogues. Drugs Future 18:29–48, 1993.Google Scholar
  94. 94.2
    Schirner M, Schneider M: Cicaprost does not affect tumor inhibitory potential of cytostatic drugs. Anticancer Res 13:743–746, 1993.PubMedGoogle Scholar
  95. 95.2
    Shirner M, Shneider MR: Cicaprost inhibits metastases of animal tumors. Prostaglandins 42:451–461, 1991.CrossRefGoogle Scholar
  96. 96.2
    Shirner M, Lichter RB, Schneider MR: The stable prostacyclin analogue cicaprost inhibits metastasis to lungs and lymph nodes in the 1376NF MTLn3 rat mammary carcinoma. Clin Exp Metastasis 12:24–30, 1994.CrossRefGoogle Scholar
  97. 97.2
    Schulman S, Granqvist S, Holmstrom M, et al. Duration of Anticoagulant Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336:393–398, 1997.PubMedCrossRefGoogle Scholar
  98. 98.2
    Semeraro N, Colucci M: Tissue factor in health and disease. Thromb Haemost 78:759–764, 1997.PubMedGoogle Scholar
  99. 99.2
    Shands JW: Macrophage procoagulants. Hemostasis 14:373–377, 1984.Google Scholar
  100. 100.2
    Silverstein TR, Nachman RL: Cancer and clotting: Trousseau warning. N Engl J Med 327:1163–1164, 1992.PubMedGoogle Scholar
  101. 101.2
    Sorensen HT, Mellemkiaer L, Steffensen FH, et al: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338:1169–1173, 1998.PubMedCrossRefGoogle Scholar
  102. 102.2
    Skelly MM, Troy A, Duffy MJ, et al: Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 3:1837–1840, 1997.PubMedGoogle Scholar
  103. 103.2
    Sun NCJ, McAfee WM, Hum GJ, et al: Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Pathol 71:10–16; 1979.PubMedGoogle Scholar
  104. 104.2
    Tang DG, Chen YQ, Newman PJ, et al: Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J Biol Chem 268:22883–22894, 1993.PubMedGoogle Scholar
  105. 105.2
    Tetu B, Brisson J, Lapointe H, et al: Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. Hum Pathol 29:979–985, 1998.PubMedCrossRefGoogle Scholar
  106. 106.2
    The Columbus Investigators. Low Molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337:657–662, 1997.CrossRefGoogle Scholar
  107. 107.2
    Thornes RD: Fibrinolytic therapy of leukemia. J R Coll Surg Ireland 6:123–128, 1971.Google Scholar
  108. 108.2
    Trikha M, Raso E, Cai Y, et al: Role of alphaII(b)beta3 integrin in prostate cancer metastasis. Prostate 35:185–192, 1998.PubMedCrossRefGoogle Scholar
  109. 109.2
    Trousseau A: Phlegmasia alba dolens. Lecture on clinical medicine, delivered at the Hotel-Dieu, Paris. London: New Sydenham Society, 281–295, 1872.Google Scholar
  110. 110.2
    Ustundag Y, Can U, Benli S, et al: N. Internal carotid occlusion in a patient with malignant peritoneal mesothelioma: it is a sign of malignancy-related thrombosis? Am J Med Sci 319:265–267, 2000.PubMedCrossRefGoogle Scholar
  111. 111.2
    Vallejo CT Rabinovich MG, Perez JE, et al: High-dose cisplatin with dipyridamole in advanced non-small cell lung cancer. A Grupo Oncologico Cooperativo del Sur Study. Am J Clin Oncol Cancer Clin Trial 18:185–188, 1995.Google Scholar
  112. 112.2
    Van de Water L, Tracy PB, Aronson D, et al: Tumor cell generation of thrombin via prothrombinase assembly. Cancer Res 45: 5521–5525, 1985.Google Scholar
  113. 113.2
    von Tempelhoff GF, Dietrich M, Niemann F, et al: Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 77:456–461, 1997.Google Scholar
  114. 114.2
    Wada H Sakuragawa N, Mari Y, et al: Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 60:273–278, 1999.PubMedCrossRefGoogle Scholar
  115. 115.2
    Winkley JM, Adams HP jr. Potential role of abciximab in ischemic cerebrovascular disease. Am J Cardiol 85:47C-51C, 2000.PubMedCrossRefGoogle Scholar
  116. 116.2
    Wester JPJ, deValk HW, Nieuwenhuis HK, et al: Risk factors for bleed during treatment of acute venous thromboembolism. Thromb Haemost 76:682–688, 1996.PubMedGoogle Scholar
  117. 117.2
    Zacharski TR, Henderson WG, Rickles FR, et al: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study 75. Cancer 53:2046–2052, 1984.PubMedCrossRefGoogle Scholar
  118. 118.2
    Zacharski LR, Wojtukiewicz MZ, Costantini W, et al: Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 18:104–116, 1992.PubMedCrossRefGoogle Scholar
  119. 119.2
    Zurbron KH, Gram J, Glander K, et al: Influence of cytostatic treatment on the coagulation system and fibrinolysis in patient with non-Hodgkin’s lymphomas and acute leukemias. Eur J Haematol 47:55–59, 1991Google Scholar

Copyright information

© Arányi Lajos Foundation 2000

Authors and Affiliations

  • M. F. Loreto
    • 1
  • Massimo De Martinis
    • 1
  • M. P. Corsi
    • 1
  • M. Modesti
    • 1
  • L. Ginaldi
    • 1
  1. 1.Department of Internal Medicine and Public HealthUniversity of L’AquilaL’AquilaItaly

Personalised recommendations